Targeting the Wnt signaling pathway to augment bone formation

Current Osteoporosis Reports

Volumn 6, Issue 4, 2008, Pages 142-148

  Shahnazari, Mohammad ^b   Yao, Wei ^b   Corr, Maripat ^b   Lane, Nancy E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; DICKKOPF 1 PROTEIN; GLUCOCORTICOID; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CHLORIDE; PARATHYROID HORMONE; PROTEIN WIF1; SCLEROSTIN; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; UNCLASSIFIED DRUG; WNT PROTEIN; BONE MORPHOGENETIC PROTEIN; DKK1 PROTEIN, HUMAN; SIGNAL PEPTIDE; SOST PROTEIN, HUMAN;

BONE DEVELOPMENT; CANCER GROWTH; CELL DIFFERENTIATION; CELL FUNCTION; CLEIDOCRANIAL DYSPLASIA; DRUG MECHANISM; HOMEOSTASIS; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ARTICLE; BONE; GENETIC MARKER; METABOLISM; PHYSIOLOGY;

BONE AND BONES; BONE MORPHOGENETIC PROTEINS; GENETIC MARKERS; HOMEOSTASIS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; OSTEOGENESIS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 61449361112     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-008-0025-5     Document Type: Review

References (75)

1. Fuerer C, Nusse R, Ten Berge D: Wnt signalling in development and disease. Max Delbruck Center for Molecular Medicine meeting on Wnt signaling in development and disease. EMBO Rep 2008, 9:134-138.
2. Nusse R, Varmus HE: Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982, 31:99-109.
3. Gong Y, Slee RB, Fukai N, et al.: LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107:513-523.
4. Little RD, Carulli JP, Del Mastro RG, et al.: A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002, 70:11-19.
5. Huang H, He X: Wnt/betN-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol 2008, 20:119-125.
6. Gordon MDM Nusse R: Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006, 281:22429-22433.
7. Bennett CN, Longo KA, Wright WS, et al.: Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A 2005, 102:3324-3329.
8. Andrade AC, Nilsson O, Barnes KM, Baron J: Wnt gene expression in the post-natal growth plate: Regulation with chondrocyte differentiation. Bone 2007, 40:1361-1369.
9. Rodda SJ, McMahon AP: Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 2006, 133:3231-3244.
10. Dong YF, Soung do Y, Schwarz EM, et al.: Wnt induction of chondrocyte hypertrophy through the Runx2 transcription factor. J Cell Physiol 2006, 208:77-86.
11. Bennett CN, Ouyang H, Ma YL, et al.: Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J Bone Miner Res 2007, 22:1924-1932.
12. Glass DA 2nd, Bialek P, Ahn JD, et al.: Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005, 8:751-764.
13. Tu X, Joeng KS, Nakayama KI, et al.: Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation. Dev Cell 2007, 12:113-127.
14. Bergenstock MK, Partridge NC: Parathyroid hormone stimulation of noncanonical Wnt signaling in bone. Ann N Y Acad Sci 2007, 1116:354-359.
15. Chang J, Sonoyama W, Wang Z, et al.: Noncanonical Wnt-4 signaling enhances bone regeneration of mesenchymal stem cells in craniofacial defects through activation of p38 MAPK. J Biol Chem 2007, 282:30938-30948.
16. Takada I, Suzawa M, Matsumoto K, Kato S: Suppression of PPAR transactivation switches cell fate of bone marrow stem cells from adipocytes into osteoblasts. Ann N Y Acad Sci 2007, 116:182-195.
17. Yamaguchi TP, Bradley A, McMahon AP, Jones S: A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. Development 1999, 126:1211-1223.
18. Almeida M, Han L, Bellido T, et al.: Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and-independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 2005, 280:41342-41351.
19. Mao B, Wu W, Davidson G, et al.: Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 2002, 417:664-667.
20. Kulkarni NH, Wei T, Kumar A, et al.: Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor. J Cell Biochem 2007, 102:1504-1518.
21. Baron R, Rawadi G: Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007, 148:2635-2643.
22. Sims AM, Shephard N, Carter K, et al.: Genetic analyses in a sample of individuals with high or low BMD shows association with multiple Wnt pathway genes. J Bone Miner Res 2008, 23:499-506.
23. Klaus A, Birchmeier W: Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008, 8:387-398.
24. Glinka A, Wu W, Delius H, et al.: Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998, 391:357-362.
25. Mao B, Wu W, Li Y, et al.: LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001, 411:321-325.
26. Li X, Liu P, Liu W, et al.: Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet 2005, 37:945-952.
27. van der Horst G, van der Werf SM, et al.: Down-regulation of Wnt signaling by increased expression of Dickkopf-1 and-2 is a prerequisite for late-stage osteoblast differentiation of KS483 cells. J Bone Miner Res 2005, 20:1867-1877.
28. Li J, Sarosi I, Cattley RC, et al.: Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 2006, 39:754-766.
29. Morvan F, Boulukos K, Clement-Lacroix P, et al.: Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006, 21:934-945.
30. Qiang YW, Chen Y, Stephens O, et al.: Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: A potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008, 112:196-207.
31. Matsumoto T, Abe M: Bone destruction in multiple myeloma. Ann N Y Acad Sci 2006, 1068:319-326.
32. Heider U, Hofbauer LC, Zavrski I, et al.: Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem Biophys Res Commun 2005, 338:687-693.
33. Oshima T, Abe M, Asano J, et al.: Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005, 106:3160-315.
34. Hall CL, Keller ET: The role of Wnts in bone metastases. Cancer Metastasis Rev 2006, 25:551-558.
35. Voorzanger-Rousselot N, Goehrig D, Journe F, et al.: Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 2007, 97:964-970.
36. Hurson CJ, Butler JS, Keating DT, et al.: Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis. BMC Musculoskelet Disord 2007, 8:12.
37. Yao W, Cheng Z, Busse C, et al.: Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: A longitudinal study of gene expression in bone tissue from glucocorticoidtreated mice. Arthritis Rheum 2008, 58:1674-1686.
38. Wang FS, Ko JY, Yeh DW, et al.: Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 2008, 149:1793-1801.
39. Wang FS, Ko JY, Lin CL, et al.: Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. Bone 2007, 40:485-492.
40. Diarra D, Stolina M, Polzer K, et al.: Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156-163.
41. Yaccoby S, Ling W, Zhan F, et al.: Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007, 109:2106-2111.
42. Balemans W, Ebeling M, Patel N, et al.: Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10:537-543.
43. Irie K, Ejiri S, Sakakura Y, et al.: Matrix mineralization as a trigger for osteocyte maturation. J Histochem Cytochem 2008, 56:561-567.
44. Poole KE, van Bezooijen RL, Loveridge N, et al.: Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005, 19:1842-1844.
45. Kusu N, Laurikkala J, Imanishi M, et al.: Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 2003, 278:24113-24117.
46. Sutherland MK, Geoghegan JC, Yu C, et al.: Sclerostin promotes the apoptosis of human osteoblastic cells: A novel regulation of bone formation. Bone 2004, 35:828-835.
47. Balemans W, Piters E, Cleiren E, et al.: The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif Tissue Int 2008 Jun 3 (Epub ahead of print).
48. Semenov MV, He X: LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem 2006, 281:38276-38284.
49. Li X, Ominsky MS, Niu QT, et al.: Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008, 23:860-869.
50. Bellido T: Downregulation of SOST/scAerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes. J Musculoskelet Neuronal Interact 2006, 6:358-359.
51. Robling AG, Niziolek PJ, Baldridge LA, et al.: Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008, 283:5866-5875.
52. Padhi D, Stouch B, Jang G, et al.: Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. Abstracts of the 29th Annual Meeting of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22(Suppl 1):S37.
53. Bovolenta P, EsteNe P, Ruiz JM, et al.: Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci 2008, 121(Pt 6):737-746.
54. Hoang B, Moos M Jr, Vukicevic S, Luyten FP: Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal morphogenesis. J Biol Chem 1996, 271:26131-26137.
55. Chung YS, Baylink DJ, Srivastava AK, et al.: Effects of secreted frizzled-related protein 3 on osteoblasts in vitro. J Bone Miner Res 2004, 19:1395-1402.
56. Boland GM, Perkins G, Hall DJ, Tuan RS: Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 2004, 93:1210-1230.
57. Mandal D, Srivastava A, Mahlum E, et al.: Severe suppression of Frzb/ sFRP3 transcription in osteogenic sarcoma. Gene 2007, 386:131-138.
58. Min JL, Meulenbelt I, Riyazi N, et al.: Association of the Frizzled-related protein gene with symptomatic osteoarthritis at multiple sites. Arthritis Rheum 2005, 52:1077-1080.
59. Lane NE, Nevitt MC, Lui LY, et al.: Wnt signaling antagonists are potential prognostic biomarkers for the progression of radiographic hip osteoarthritis in elderly Caucasian women. Arthritis Rheum 2007, 56:3319-3325.
60. Bodine PV, Billiard J, Moran RA, et al.: The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem 2005, 96:1212-1230.
61. Bodine PV, Seestaller-Wehr L, Kharode YP, et al.: Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J Cell Physiol 2007, 210:352-357.
62. Yao W, Cheng Z, Busse C, et al.: Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates pth bone anabolic effects [abstract]. Presented at the 30th Annual Meeting of the American Society for Bone and Mineral Research. Montreal, Quebec, Canada; September 12-16, 2008.
63. Hausler KD, Horwood NJ, Chuman Y, et al.: Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation. J Bone Miner Res 2004, 19:1873-1881.
64. Liu D, Wise GE: A DNA microarray analysis of chemokine and receptor genes in the rat dental follicle - role of secreted frizzled-related protein-1 in osteoclastogenesis. Bone 2007, 41:266-272.
65. Bodine PV, Zhao W, Kharode YP, et al.: The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 2004, 18:1222-1237.
66. Bodine P, Stauffer B, Ponce-de-Leon H, et al.: A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein (SFRP)-1 stimulates bone formation. Abstracts of the 29th Annual Meeting of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22(Suppl 1):S4.
67. Nakanishi R, Shimizu M, Mori M, et al.: Secreted frizzledrelated protein 4 is a negative regulator of peak BMD in SAMP6 mice. J Bone Miner Res 2006, 21:1713-1721.
68. Nakanishi R, Akiyama H, Kimura H, et al.: Osteoblast-targeted expression of Sfrp4 in mice results in low bone mass. J Bone Miner Res 2008, 23:271-277.
69. Berndt T, Craig TA, Bowe AE, et al.: Secreted frizzledrelated protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 2003, 112:785-794.
70. Vaes BL, Dechering KJ, van Someren EP, et al.: Microarray analysis reveals expression regulation of Wnt antagonists in differentiating osteoblasts. Bone 2005, 36:803-811.
71. Clement-Lacroix P, Ai M, Morvan F, et al.: Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A 2005, 102:17406-17411.
72. Kulkarni NH, Onyia JE, Zeng Q, et al.: Orally bioavailable GSK-3alpha/ beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 2006, 21:910-920.
73. Vestergaard P, Rejnmark L, Mosekilde L: Reduced relative risk of fractures among users of lithium. Calcif Tissue Int 2005, 77:1-8.
74. Kugimiya F, Kawaguchi H, Ohba S, et al.: GSK-3beta controls osteogenesis through regulating Runx2 activity. PLoS ONE 2007, 2:e837.
75. Ougolkov AV, Bone ND, Fernandez-Zapico ME, et al.: Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007, 110:735-742.